menu
    • menu
    [{"orgOrder":0,"company":"MEDICE Health Family","sponsor":"Erkim","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"TURKEY","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"Vadadustat","moa":"Egl nine homolog 1 | Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"MEDICE Health Family","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"MEDICE Health Family \/ MEDICE Health Family","highestDevelopmentStatusID":"15","companyTruncated":"MEDICE Health Family \/ MEDICE Health Family"},{"orgOrder":0,"company":"MEDICE Health Family","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Vitamin B12","moa":"Methionine synthase|Methylmalonyl-CoA mutase, mitochondrial|Methionine synthase reductase|Methylmalonic aciduria type A protein, mitochondrial|Cyanocobalamin reductase \/ alkylcobalamin dealkylase|Methylenetetrahydrofolate reductase (NADPH)","graph1":"Hematology","graph2":"Phase IV","graph3":"MEDICE Health Family","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEDICE Health Family \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"MEDICE Health Family \/ Undisclosed"},{"orgOrder":0,"company":"MEDICE Health Family","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Niacinamide","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Nephrology","graph2":"Phase II","graph3":"MEDICE Health Family","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEDICE Health Family \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MEDICE Health Family \/ Undisclosed"},{"orgOrder":0,"company":"MEDICE Health Family","sponsor":"University Hospital Muenster","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Benzalkonium Chloride-Benzocaine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"MEDICE Health Family","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEDICE Health Family \/ University Hospital Muenster","highestDevelopmentStatusID":"11","companyTruncated":"MEDICE Health Family \/ University Hospital Muenster"},{"orgOrder":0,"company":"MEDICE Health Family","sponsor":"Dr. Wiedey GmbH - Institut F\u00fcr Klinische Forschung | Medidata Dr M\u00f6ller","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Restharrow Root Extract","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MEDICE Health Family","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEDICE Health Family \/ Dr. Wiedey GmbH - Institut F\u00fcr Klinische Forschung | Medidata Dr M\u00f6ller","highestDevelopmentStatusID":"10","companyTruncated":"MEDICE Health Family \/ Dr. Wiedey GmbH - Institut F\u00fcr Klinische Forschung | Medidata Dr M\u00f6ller"},{"orgOrder":0,"company":"MEDICE Health Family","sponsor":"Prim. Priv. Doz. Dr. Daniel Cejka","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Sodium Bicarbonate","moa":"Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)","graph1":"Immunology","graph2":"Phase II","graph3":"MEDICE Health Family","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MEDICE Health Family \/ Prim. Priv. Doz. Dr. Daniel Cejka","highestDevelopmentStatusID":"8","companyTruncated":"MEDICE Health Family \/ Prim. Priv. Doz. Dr. Daniel Cejka"}]

    Find Clinical Drug Pipeline Developments & Deals by MEDICE Health Family

    Menu

    MEDICE Health Family

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MEDICE Health Family

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            MEDICE Health Family

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vitamin B12

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Injectable Vs Oral Vitamin Combination

                            Details : Vitamin B12 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Vitamin B 12 Deficiency.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            June 19, 2025

                            Lead Product(s) : Vitamin B12

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MEDICE Health Family

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            MEDICE Health Family

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vadadustat

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Recipient : Erkim

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Er-Kim Announces Distribution Agreement with MEDICE for Vafseo® in Europe

                            Details : Under the agreement, Er-Kim partner with the MEDICE to commercialize the Vafseo (vadadustat). It is being indicated for the treatment of of symptomatic anaemia associated with CKD in adults.

                            Product Name : Vafseo

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 14, 2025

                            Lead Product(s) : Vadadustat

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Recipient : Erkim

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MEDICE Health Family

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            MEDICE Health Family

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Restharrow Root Extract

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Dr. Wiedey GmbH - Institut Für Klinische Forschung | Medidata Dr Möller

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Tolerability of a Phytotherapy Combination (Aqualibra) in Patients With Uncomplicated Cystitis

                            Details : Restharrow Root Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Tract Infections.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            July 25, 2019

                            Lead Product(s) : Restharrow Root Extract

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Dr. Wiedey GmbH - Institut Für Klinische Forschung | Medidata Dr Möller

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MEDICE Health Family

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            MEDICE Health Family

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Benzalkonium Chloride-Benzocaine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : University Hospital Muenster

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of a Sore Throat Lozenge DORITHRICIN in Patients With Acute Pharyngitis

                            Details : Benzalkonium Chloride-Benzocaine is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pharyngitis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 27, 2017

                            Lead Product(s) : Benzalkonium Chloride-Benzocaine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : University Hospital Muenster

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MEDICE Health Family

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            MEDICE Health Family

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Bicarbonate

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Prim. Priv. Doz. Dr. Daniel Cejka

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effect of Sodium Bicarbonate (Nephrotrans®) on Calcification Propensity of Serum in Kidney Transplant R...

                            Details : Sodium Bicarbonate is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Graft Rejection.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            October 04, 2017

                            Lead Product(s) : Sodium Bicarbonate

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Prim. Priv. Doz. Dr. Daniel Cejka

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            MEDICE Health Family

                            Germany arrow
                            CPhI India
                            Not Confirmed

                            MEDICE Health Family

                            Germany arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nicotinamide in Hemodialysis Patients With Hyperphosphatemia

                            Details : Nicotinamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 14, 2010

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth